{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:58:52Z","timestamp":1785473932545,"version":"3.56.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"Supplement_A","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-15-RHU-0004"],"award-info":[{"award-number":["ANR-15-RHU-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-15-IDEX-04-LUE"],"award-info":[{"award-number":["ANR-15-IDEX-04-LUE"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/eurheartj\/suy032","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:04:54Z","timestamp":1551179094000},"page":"A48-A54","source":"Crossref","is-referenced-by-count":13,"title":["A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology"],"prefix":"10.1093","volume":"21","author":[{"given":"Patrick","family":"Rossignol","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d'Investigations Cliniques- Plurith\u00e9matique 1433, Inserm U1116, CHRU Nancy, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Association Lorraine de Traitement de l'Insuffisance R\u00e9nale, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"key\n\t\t\t\t2019022808504870000_suy032-B1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume-title":"Am J Kidney Dis","year":"2004"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B2","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B3"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B4","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B5","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","article-title":"The double challenge of resistant hypertension and chronic kidney disease","volume":"386","author":"Rossignol","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2010.04.004","article-title":"HFSA 2010 comprehensive heart failure practice guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B7","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"ACCF\/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol 2013"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B9","author":"Agency"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B10","author":"Agency"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis","volume":"39","author":"Kovesdy","year":"2018","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B13","first-page":"104","article-title":"Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data","volume":"38","author":"Krogager","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","article-title":"Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction","volume":"1","author":"Krogager","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00392-017-1173-3","article-title":"Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications","volume":"107","author":"Legrand","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B16","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B17","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"Nunez","year":"2018","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.ajkd.2006.02.182","article-title":"Microalbuminuria as a target to improve cardiovascular and renal outcomes","volume":"47","author":"Basi","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B22","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1464-5491.2011.03341.x","article-title":"Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis","volume":"28","author":"Blacklock","year":"2011","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajh\/hps038","article-title":"Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis","volume":"26","author":"Susantitaphong","year":"2013","journal-title":"Am J Hypertens"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B24","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B25","doi-asserted-by":"crossref","first-page":"d4891","DOI":"10.1136\/bmj.d4891","article-title":"Management of hypertension: summary of NICE guidance","volume":"343","author":"Krause","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cpt.746","article-title":"Impact of hyperkalemia and worsening renal function on the use of renin angiotensin aldosterone system inhibitors in chronic heart failure with reduced ejection fraction","volume":"102","author":"Pitt","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B27","first-page":"s212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B28","doi-asserted-by":"crossref","first-page":"295.","DOI":"10.1186\/s12882-017-0710-7","article-title":"Association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care\u2014the NephroTest study","volume":"18","author":"Wagner","year":"2017","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B29","doi-asserted-by":"crossref","first-page":"308.","DOI":"10.1186\/s12882-017-0723-2","article-title":"Correction to: association of plasma potassium with mortality and end-stage kidney disease in patients with chronic kidney disease under nephrologist care\u2014the NephroTest study","volume":"18","author":"Wagner","year":"2017","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B30","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/ndt\/gfx053","article-title":"Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey","volume":"32","author":"Rossignol","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcard.2016.04.127","article-title":"New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: considerations for trial design and regulatory approval","volume":"216","author":"Zannad","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2016.07.032","article-title":"Potassium lowering agents: recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia","volume":"118","author":"Pitt","year":"2017","journal-title":"Pharmacol Res"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B34","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.phrs.2016.09.039","article-title":"Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future","volume":"113","author":"Rossignol","year":"2016","journal-title":"Pharmacol Res"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B36"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fca.11.71","article-title":"PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016","volume":"8","author":"Buysse","year":"2012","journal-title":"Future Cardiol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B38","doi-asserted-by":"crossref","first-page":"e114686.","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3909\/ricm0727","article-title":"Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management","volume":"15","author":"McCullough","year":"2014","journal-title":"Rev Cardiovasc Med"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B42","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B43","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000451067","article-title":"Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis","volume":"44","author":"Bushinsky","year":"2016","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B45","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B46","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.12265","article-title":"Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease","author":"Pitt","year":"2018","journal-title":"ESC Heart Fail"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B47","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000492622","article-title":"Patiromer to enable spironolactone use in the treatment of patients with resistant hypertension and chronic kidney disease: rationale and design of the AMBER study","volume":"48","author":"Agarwal","year":"2018","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B49","first-page":"113","article-title":"The association between serum potassium and mortality in patients with hypertension: \u2018a wake-up call\u2019","volume":"38","author":"Pitt","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B50","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.11904","article-title":"Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure","volume":"314","author":"Cooper","year":"2015","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B51","doi-asserted-by":"crossref","DOI":"10.1093\/ehjqcco\/qcy019","article-title":"A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure","author":"Nilsson","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"key\n\t\t\t\t2019022808504870000_suy032-B52","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehx537","article-title":"Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?","volume":"38","author":"Pitt","year":"2017","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_A\/A48\/27994229\/suy032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T16:45:50Z","timestamp":1663001150000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/21\/Supplement_A\/A48\/5364196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":52,"journal-issue":{"issue":"Supplement_A","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suy032","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}